Holen Sie sich die Stockscreener-App
700.33
0.62%
4.31
Handel nachbörslich:
700.33
Schlusskurs vom Vortag:
$696.02
Offen:
$697.93
24-Stunden-Volumen:
705.83K
Relative Volume:
0.83
Marktkapitalisierung:
$76.56B
Einnahmen:
$14.20B
Nettoeinkommen (Verlust:
$4.41B
KGV:
18.29
EPS:
38.28
Netto-Cashflow:
$3.54B
1W Leistung:
+3.97%
1M Leistung:
+1.82%
6M Leistung:
-40.92%
1J Leistung:
-26.50%
1-Tages-Spanne:
$693.07
$704.08
1-Wochen-Bereich:
$674.88
$704.08
52-Wochen-Spanne:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
2025-02-21 | Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders | NDAQ:REGN | Press Release - Stockhouse Publishing
BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
2025-02-21 | Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN) | NDAQ:REGN | Press Release - Stockhouse Publishing
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea - Korea Economic Daily
Handelsbanken Fonder AB Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Principal Securities Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Allworth Financial LP Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Everhart Financial Group Inc. Sells 508 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Hussman Strategic Advisors Inc. Purchases Shares of 2,100 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-20 | Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) | NDAQ:REGN | Press Release - Stockhouse Publishing
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure ... - The Bakersfield Californian
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman - TradingView
Shareholders that lost money on Regeneron Pharmaceuticals, - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Fagan Associates Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before March 10, 2025 to Discuss Your RightsREGN - PR Newswire
Alberta Investment Management Corp Invests $5.06 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rhumbline Advisers Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
842 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Kornitzer Capital Management Inc. KS - MarketBeat
ABC Arbitrage SA Buys New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-19 | Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
US must meet tougher standard in Regeneron kickback lawsuit - Reuters
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-02-19 | Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Class Action: Join by March 10, 2025 – Contact Levi & Korsinsky - The Octant
Callahan Advisors LLC Acquires Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Kestra Investment Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Truist Financial Corp Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Principal Financial Group Inc. - MarketBeat
REGN STOCK NEWS: Robbins LLP Reminds Regeneron - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - TradingView
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron Gets Appeals Court to Impose Tougher Kickback Standard - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
Acute Gout Flare Market to Reach New Heights in Growth by 2034, - openPR
Regeneron, Sanofi win FDA review for Dupixent update (REGN) (REGN:NASDAQ) - Seeking Alpha
This Company Just Initiated a Quarterly Dividend: Time to Buy? - MSN
Braun Stacey Associates Inc. Sells 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid - Pharmaceutical Technology
CIBC Asset Management Inc Has $24.49 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Montag A & Associates Inc. Sells 644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) - The Manila Times
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):